Membrane dynamics, cholesterol homeostasis, and Alzheimer's disease

Journal of Lipid Research

Volumn 44, Issue 11, 2003, Pages 2019-2029

  Chauhan, Neelima B ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

amyloid precursor; Apolipoprotein E; Caveolae; Glycophosphatidylinositol; Lipid raft; Protein processing

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CHOLESTEROL; GARLIC EXTRACT; GLYCOSYLPHOSPHATIDYLINOSITOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEMBRANE PROTEIN; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

ALZHEIMER DISEASE; CELL MEMBRANE; CLINICAL TRIAL; DRUG EFFICACY; DYNAMICS; GASTROINTESTINAL HEMORRHAGE; HEREDITY; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; LIVER TOXICITY; MEMBRANE STRUCTURE; MUSCLE DISEASE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROCESSING; SENILE PLAQUE; SHORT SURVEY; TOXICITY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APOLIPOPROTEINS E; CELL MEMBRANE; CHOLESTEROL; HOMEOSTASIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 0344667494     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.R300010-JLR200     Document Type: Short Survey

References (154)

1. Korn, E. D. 1969. Current concepts of membrane structure and function. Fed. Proc. 28: 6-11.
2. Damer, D. W. 1971. An alternative model for molecular organization in biological membranes. J. Bioenerg. 3: 237-246.
3. Chapman, D. 1974. Biological membranes. Biomembranes. 4A: 123-158.
4. Marsh, D. 1975. Spectroscopic studies of membrane structure. Essays Biochem. 11: 139-180.
5. Singer, S. J., and G. L. Nicolson. 1972. The fluid mosaic model of the structure of cell membranes. Science. 175: 720-731.
6. Lenard, J., and S. J. Singer. 1966. Protein conformation in cell membrane preparations as studied by optical rotatory dispersion and circular dichorism. Proc. Natl. Acad. Sci. USA. 56: 1828-1835.
7. Glaser, M., H. Simpkins, S. J. Singer, M. Sheetz, and S. I. Chan. 1970. On the interactions of lipids and proteins in the red blood cell membrane. Proc. Natl. Acad. Sci. USA. 65: 721-728.
8. Singer, S. J., and G. L. Nicolson. 1971. The structure and chemistry of mammalian cell membranes. Amer. J. Pathol. 65: 427-437.
9. Sankaram, M. B., and T. E. Thompson. 1990. Modulation of phospholipid acyl chain order by cholesterol. A solid-state 2H nuclear magnetic resonance study. Biochemistry. 29: 10676-10684.
10. Simons, K., and E. Ikonen. 1997. Functional rafts in cell membranes. Nature. 387: 569-572.
11. Brown, D. A., and E. London. 1998. Functions of lipid rafts in biological membranes. Annu. Rev. Cell Dev. Biol. 14: 111-136.
12. Klausner, R. D., A. M. Kleinfeld, R. L. Hoover, and M. J. Karnovsky. 1980. Lipid domains in membranes. Evidence derived from structural perturbations induced by free fatty acids and life-time heterogeneity analysis. J. Biol. Chem. 255: 1286-1295.
13. Simons, K., and G. van Meer. 1988. Lipid sorting in epithelial cells. Biochemistry. 27: 6197-6202.
14. van Meer, G., and K. Simons. 1988. Lipid polarity and sorting in epithelial cells. J. Cell. Biochem. 36: 51-58.
15. Edidin, M. 2003. The state of lipid rafts: from model membranes to cells. Annu. Rev. Biophys. Biomol. Struct. 32: 257-283.
16. Suzuki, T. 2002. Lipid rafts at postsynaptic sites: distribution, function and linkage to postsynaptic density. Neurosci. Res. 44: 1-9.
17. Abrami, L., M. Fivaz, T. Kobayashi, T. Kinoshita, R. G. Parton, and F. G. van der Goot. 2001. Cross-talk between caveolae and glycosylphosphatidylinositol-rich domains. J. Biol. Chem. 276: 30729-30736.
18. Dietschy, J. M., and S. D. Turley. 2001. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 12: 105-112.
19. van Meer, G. 1989. Lipid traffic in animal cells. Annu. Rev. Cell Biol. 5: 247-275.
20. Brugger, B., R. Sandhoff, S. Wegehingel, K. Gorgas, J. Malsam, J. B. Helms, W. D. Lehmann, W. Nickel, and F. T. Wieland. 2000. Evidence for segregation of sphingomyelin and cholesterol during formation of COPI-coated vesicles. J. Cell Biol. 151: 507-518.
21. Mukherjee, S., and F. R. Maxfield. 2000. Role of membrane organization and membrane domains in endocytic lipid trafficking. Traffic. 1: 203-211.
22. Puri, V., R. Watanabe, M. Dominguez, X. Sun, C. L. Wheatley, D. L. Marks, and R. E. Pagano. 1999. Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage diseases. Nat. Cell Biol. 1: 386-388.
23. Dermine, J. F., S. Duclos, J. Garin, F. St-Louis, S. Rea, R. G. Parton, and M. Desjardins. 2001. Flotillin-1-enriched lipid raft domains accumulate on maturing phagosomes. J. Biol. Chem. 276: 18507-18512.
24. Smart, E. J., G. A. Graf, M. A. McNiven, W. C. Sessa, J. A. Engelman, P. E. Scherer, T. Okamoto, and M. P. Lisanti. 1999. Caveolins, liquid-ordered domains, and signal transduction. Mol. Cell Biol. 19: 7289-7304.
25. Simons, K., and D. Toomre. 2000. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1: 31-39.
26. Cremesti, A. E., F. M. Goni, and R. Kolesnick. 2002. Role of sphingomyelinase and ceramide in modulating rafts: do biophysical properties determine biologic outcome? FEBS Lett. 531: 47-53.
27. Chamberlain, L. H., R. D. Burgoyne, and G. W. Gould. 2001. SNARE proteins are highly enriched in lipid rafts in PCI2 cells: implications for the spatial control of exocytosis. Proc. Natl. Acad. Sci. USA. 98: 5619-5624.
28. Pierini, L. M., and F. R. Maxfield. 2001. Flotillas of lipid rafts fore and aft. Proc. Natl. Acad. Sci. USA. 98: 9471-9473.
29. Harder, T., P. Scheiffele, P. Verkade, and K. Simons. 1998. Lipid domain structure of the plasma membrane revealed by patching of membrane components. J. Cell Biol. 141: 929-942.
30. Podar, K., Y. T. Tai, C. E. Cole, T. Hideshima, M. Sattler, A. Hamblin, N. Mitsiades, R. L. Schlossman, F. E. Davies, G. J. Morgan, N. C. Munshi, D. Chauhan, and K. C. Anderson. 2003. Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J. Biol. Chem. 278: 5794-5801.
31. Kogo, H., M. Shioya, Y. Takahashi, and T. Fujimoto. 1997. Caveolac and endoplasmic reticulum: immunofluorescence microscopy and time-lapse analysis. Acta Histochem. et Cytochem. 30: 593-599.
32. Fujimoto, T., H. Hagiwara, T. Aoki, H. Kogo, and R. Nomura. 1998. Caveolae: from a morphological point of view. J. Electron Microsc. (Tokyo). 47: 451-460.
33. Drab, M., P. Verkade, M. Elger, M. Kasper, M. Lohn, B. Lauterbach, J. Menne, C. Lindschau, F. Mende, F. C. Luft, A. Schedl, H. Haller, and T. V. Kurzchalia. 2001. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293: 2449-2452.
34. Razani, B., and M. P. Lisanti. 2001. Caveolin-deficient mice: insights into caveolar function human disease. J. Clin. Invest. 108: 1553-1561.
35. Murata, M., J. Peranen, R. Schreiner, F. Wieland, T. V. Kurzchalia, and K. Simons. 1995. VIP21/caveolin is a cholesterol-binding protein. Proc. Natl. Acad. Sci. USA. 92: 10339-10343.
36. Hailstones, D., L. S. Sleer, R. G. Parton, and K. K. Stanley. 1998. Regulation of caveolin and caveolae by cholesterol in MDCK cells. J. Lipid Res. 39: 369-379.
37. Parton, R. G., and K. Simons. 1995. Digging into caveolae. Science. 269: 1398-1399.
38. Okamoto, T., A. Schlegel, P. E. Scherer, and M. P. Lisanti. 1998. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J. Biol. Chem. 273: 5419-5422.
39. Mayor, S., S. Sabharanjak, and F. R. Maxfield. 1998. Cholesterol-dependent retention of GPI-anchored proteins in endosomes. EMBO J. 17: 4626-4638.
40. Simons, M., P. Keller, J. Dichgans, and J. B. Schulz. 2001. Cholesterol and Alzheimer's disease: is there a link? Neurology. 57: 1089-1093.
41. Fisher, C. A., R. S. Kiss, G. A. Francis, P. Gao, and R. O. Ryan. 1999. Human apolipoprotein E N-terminal domain displacement of apolipophorin III from insect low density lipophorin creates a receptor-competent hybrid lipoprotein. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 122: 447-451.
42. Poirier, J. 1994. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 17: 525-530.
43. Weisgraber, K. H., and R. W. Mahley. 1996. Human apolipoprotein E: the Alzheimer's disease connection. FASEB J. 10: 1485-1494.
44. Morell, P., and H. Jurevics. 1996. Origin of cholesterol in myelin. Neurochem. Res. 21: 463-470.
45. Kabara, J. J. 1973. A critical review of brain cholesterol metabolism. Prog. Brain Res. 40: 363-382.
46. Mahley, R. W. 1988. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240: 622-630.
47. Bjorkhem, I., D. Lutjohann, U. Diczfalusy, L. Stahle, G. Ahlborg, and J. Wahren. 1998. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J. Lipid Res. 39: 1594-1600.
48. Racchi, M., R. Baetta, N. Salvietti, P. Ianna, G. Franceschini, R. Paoletti, R. Fumagalli, S. Govoni, M. Trabucchi, and M. Soma. 1997. Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Biochem. J. 322: 893-898.
49. Schroeder, F., G. Nemecz, W. G. Wood, C. Joiner, G. Morrot, M. Ayraut-Jarrier, and P. F. Devaux. 1991. Transmembrane distribution of sterol in the human erythrocyte. Biochim. Biophys. Acta. 1066: 183-192.
50. Weidemann, A., G. Konig, D. Bunke, P. Fischer, J. M. Salbaum, C. L. Masters, and K. Beyreuther. 1989. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell. 57: 115-126.
51. Selkoe, D.J. 1994. Normal and abnormal biology of the beta-amyloid precursor protein. Annu. Rev. Neurosci. 17: 489-517.
52. Kang, J., H. G. Lemaire, A. Unterbeck, J. M. Salbaum, C. L. Masters, K. H. Grzeschik, G. Multhaup, K. Beyreuther, and B. Muller-Hill. 1987. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 325: 733-736.
53. Haass, C., E. H. Koo, A. Mellon, A. Y. Hung, and D. J. Selkoe. 1992. Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature. 357: 500-503.
54. Seubert, P., C. Vigo-Pelfrey, F. Esch, M. Lee, H. Dovey, D. Davis, S. Sinha, M. Schlossmacher, J. Whaley, C. Swindlehurst, R. McCormack, R. Wolfert, D. Selkoe, I. Lieberburg, and D. Schenk. 1992. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature. 359: 325-327.
55. Masliah, E., M. Mallory, N. Ge, and T. Saitoh. 1992. Amyloid precursor protein is localized in growing neurites of neonatal rat brain. Brain Res. 593: 323-328.
56. Mills, J., and P. B. Reiner. 1999. Regulation of amyloid precursor protein cleavage. J. Neurochem. 72: 443-460.
57. Atwood, C. S., G. Perry, and M. A. Smith. 2003. Cerebral hemorrhage and amyloid-beta. Science. 299: 1014.
58. Maruyama, K., F. Kametani, M. Usami, W. Yamao-Harigaya, and K. Tanaka. 1991. "Secretase," Alzheimer amyloid protein precursor secreting enzyme is not sequence-specific. Biochem. Biophys. Res. Commun. 179: 1670-1676.
59. Anderson, J. P., F. S. Esch, P. S. Keim, K. Sambamurti, I. Lieberburg, and N. K. Robakis. 1991. Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells. Neurosci. Lett. 128: 126-128.
60. Sisodia, S. S. 1992. Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc. Natl. Acad. Sci. USA. 89: 6075-6079.
61. Bodovitz, S., and W. L. Klein. 1996. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J. Biol. Chem. 271: 4436-4440.
62. Puglielli, L., G. Konopka, E. Pack-Chung, L. A. Ingano, O. Berezovska, B. T. Hyman, T. Y. Chang, R. E. Tanzi, and D. M. Kovacs. 2001. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell. Biol. 3: 905-912.
63. Runz, H., J. Rietdorf, I. Tomic, M. de Bernard, K. Beyreuther, R. Pepperkok, and T. Hartmann. 2002. Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J. Neurosci. 22: 1679-1689.
64. Simons, M., P. Keller, B. De Strooper, K. Beyreuther, C. G. Dotti, and K. Simons. 1998. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA. 95: 6460-6464.
65. Fassbender, K., M. Simons, C. Bergmann, M. Stroick, D. Lutjohann, P. Keller, H. Runz, S. Kuhl, T. Bertsch, K. von Bergmann, M. Hennerici, K. Beyreuther, and T. Hartmann. 2001. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 98: 5856-5861.
66. Kojro, E., G. Gimpl, S. Lammich, W. Marz, and F. Fahrenholz. 2001. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc. Natl. Acad. Sci. USA. 98: 5815-5820.
67. Frears, E. R., D. J. Stephens, C. E. Walters, H. Davies, and B. M. Austen. 1999. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport. 10: 1699-1705.
68. Refolo, L. M., B. Malester, J. LaFrancois, T. Bryant-Thomas, R. Wang, G. S. Tint, K. Sambamurti, K. Duff, and M. A. Pappolla. 2000. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7: 321-331.
69. Lee, S. J., U. Liyanage, P. E. Bickel, W. Xia, P. T. Lansbury Jr., and K. S. Kosik. 1998. A detergent-insoluble membrane compartment contains A beta in vivo. Nat. Med. 4: 730-734.
70. Bouillot, C., A. Prochiantz, G. Rougon, and B. Allinquant. 1996. Axonal amyloid precursor protein expressed by neurons in vitro is present in a membrane fraction with caveolae-like properties. J. Biol. Chem. 271: 7640-7644.
71. Morishima-Kawashima, M., and Y. Ihara. 1998. The presence of amyloid β-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. Biochemistry. 37: 15247-15253.
72. Parkin, E. T., A. J. Turner, and N. M. Hooper. 1999. Amyloid precursor protein, although partially detergent-insoluble in mouse cerebral cortex, behaves as an atypical lipid raft protein. Biochem. J. 344: 23-30.
73. Mizuno, T., M. Nakata, H. Naiki, M. Michikawa, R. Wang, C. Haass, and K. Yanagisawa. 1999. Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture. J. Biol. Chem. 274: 15110-15114.
74. Kakio, A., S. I. Nishimoto, K. Yanagisawa, Y. Kozutsumi, and K. Matsuzaki. 2001. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J. Biol. Chem. 276: 24985-24990.
75. Yanagisawa, K., A. Odaka, N. Suzuki, and Y. Ihara. 1995. GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat. Med. 1: 1062-1066.
76. McLaurin, J., and A. Chakrabartty. 1996. Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J. Biol. Chem. 271: 26482-26489.
77. Brown, M. S., and J. L. Goldstein. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science. 232: 34-47.
78. Handelmann, G. E., J. K. Boyles, K. H. Weisgraber, R. W. Mahley, and R. E. Pitas. 1992. Effects of apolipoprotein E, beta-very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro. J. Lipid Res. 33: 1677-1688.
79. Poirier, J., A. Baccichet, D. Dea, and S. Gauthier. 1993. Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience. 55: 81-90.
80. Nathan, B. P., S. Bellosta, D. A. Sanan, K. H. Weisgraber, R. W. Mahley, and R. E. Pitas. 1994. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science. 264: 850-852.
81. Masliah, E., M. Mallory, N. Ge, M. Alford, I. Veinbergs, and A. D. Roses. 1995. Neurodegeneration in the central nervous system of apoE-deficient mice. Exp. Neurol. 136: 107-122.
82. Masliah, E., M. Mallory, I. Veinbergs, A. Miller, and W. Samuel. 1996. Alterations in apolipoprotein E expression during aging and neurodegeneration. Prog. Neurobiol. 50: 493-503.
83. Poirier, J. 2000. Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann. N. Y. Acad. Sci. 924: 81-90.
84. Lin-Lee, Y. C., F. T. Kao, P. Cheung, and L. Chan. 1985. Apolipoprotein E gene mapping and expression: localization of the structural gene to human chromosome 19 and expression of ApoE mRNA in lipoprotein- and non-lipoprotein-producing tissues. Biochemistry. 24: 3751-3756.
85. Zannis, V. I., and J. L. Breslow. 1981. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry. 20: 1033-1041.
86. Han, X., H. Cheng, J. D. Fryer, A. M. Fagan, and D. M. Holtzman. 2003. Novel role for apolipoprotein E in the central nervous system. Modulation of sulfatide content. J. Biol. Chem. 278: 8043-8051.
87. Selkoe, D. J., and P. J. Lansbury. 1999. Biochemistry of Alzheimer's and prion diseases. In Basic Neurochemistry: Molecular, Cellular and Medical Aspects. G. J. Siegel, B. W. Agranoff, R. W. Albers, S. K. Fisher, and M. D. Uhler, editors. Lippincott-Raven, New York. 949-968.
88. Elshourbagy, N. A., W. S. Liao, R. W. Mahley, and J. M. Taylor. 1985. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc. Natl. Acad. Sci. USA. 82: 203-207.
89. Lenich, C., P. Brecher, S. Makrides, A. Chobanian, and V. I. Zannis. 1988. Apolipoprotein gene expression in the rabbit: abundance, size, and distribution of apolipoprotein mRNA species in different tissues. J. Lipid Res. 29: 755-764.
90. Boyles, J. K., R. E. Pitas, E. Wilson, R. W. Mahley, and J. M. Taylor. 1985. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J. Clin. Invest. 76: 1501-1513.
91. Pitas, R. E., J. K. Boyles, S. H. Lee, D. Foss, and R. W. Mahley. 1987. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta. 917: 148-161.
92. Pitas, R. E., T. L. Innerarity, J. N. Weinstein, and R. W. Mahley. 1981. Acetoacetylated lipoproteins used to distinguish fibroblasts from macrophages in vitro by fluorescence microscopy. Arteriosclerosis. 1: 177-185.
93. Akaaboune, M., M. Villanova, B. W. Festoff, M. Verdiere-Sahuque, and D. Hantai. 1994. Apolipoprotein E expression at neuromuscular junctions in mouse, rat and human skeletal muscle. FEBS Lett. 351: 246-248.
94. Han, S. H., C. Hulette, A. M. Saunders, G. Einstein, M. Pericak-Vance, W. J. Strittmatter, A. D. Roses, and D. E. Schmechel. 1994. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls. Exp. Neurol. 128: 13-26.
95. Boyles, J. K., L. M. Notterpek, and L.J. Anderson. 1990. Accumulation of apolipoproteins in the regenerating and remyelinating mammalian peripheral nerve. Identification of apolipoprotein D, apolipoprotein A-IV, apolipoprotein E, and apolipoprotein A-I. J. Biol. Chem. 265: 17805-17815.
96. Masliah, E., W. Samuel, I. Veinbergs, M. Mallory, M. Mante, and T. Saitoh. 1997. Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE. Brain Res. 751: 307-314.
97. Gordon, I., E. Grauer, I. Genis, E. Sehayek, and D. M. Michaelson. 1995. Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. Neurosci. Lett. 199: 1-4.
98. Oitzl, M. S., M. Mulder, P.J. Lucassen, L. M. Havekes, J. Grootendorst, and E. R. de Kloet. 1997. Severe learning deficits in apolipoprotein E-knockout mice in a water maze task. Brain Res. 752: 189-196.
99. Beffert, U., and J. Poirier. 1996. Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease. Ann. N. Y. Acad. Sci. 777: 166-174.
100. Bales, K. R., T. Verina, R. C. Dodel, Y. Du, L. Altstiel, M. Bender, P. Hyslop, E. M. Johnstone, S. P. Little, and D. J. Cummins. 1997. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17: 263-264.
101. Holtzman, D. M., K. R. Bales, S. Wu, P. Bhat, M. Parsadanian, A. M. Fagan, L. K. Chang, Y. Sun, and S. M. Paul. 1999. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J. Clin. Invest. 103: R15-R21.
102. Russo, C., G. Angelini, D. Dapino, A. Piccini, G. Piombo, G. Schettini, S. Chen, J. K. Teller, D. Zaccheo, P. Gambetti, and M. Tabaton. 1998. Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 95: 15598-15602.
103. Holtzman, D. M., A. M. Fagan, B. Mackey, T. Tenkova, L. Sartorius, S. M. Paul, K. Bales, K. H. Ashe, M. C. Irizarry, and B. T. Hyman. 2000. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann. Neurol. 47: 739-747.
104. Hartman, R. E., D. F. Wozniak, A. Nardi, J. W. Olney, L. Sartorius, and D. M. Holtzman. 2001. Behavioral phenotyping of GFAP-apoE3 and -apoE4 transgenic mice: apoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology. Exp. Neurol. 170: 326-344.
105. Fagan, A. M., M. Watson, M. Parsadanian, K. R. Bales, S. M. Paul, and D. M. Holtzman. 2002. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9: 305-318.
106. Strittmatter, W. J., A. M. Saunders, D. Schmechel, M. Pericak-Vance, J. Enghild, G. S. Salvesen, and A. D. Roses. 1993. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90: 1977-1981.
107. Roses, A. D., A. M. Saunders, E. H. Corder, M. A. Pericak-Vance, S. H. Han, G. Einstein, C. Hulette, D. E. Schmechel, M. Holsti, and D. Huang. 1995. Influence of the susceptibility genes apolipoprotein E-epsilon 4 and apolipoprotein E-epsilon 2 on the rate of disease expressivity of late-onset Alzheimer's disease. Arzneimittelforschung. 45: 413-417.
108. Saunders, A. M., O. Hulette, K. A. Welsh-Bohmer, D. E. Schmechel, B. Crain, J. R. Burke, M. J. Alberts, W. J. Strittmatter, J. C. Breitner, and C. Rosenberg. 1993. Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet. 348: 90-93.
109. Saunders, A. M. 2000. Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses. J. Neuropathol. Exp. Neurol. 59: 751-758.
110. Benzing, W. C., and E. J. Mufson. 1995. Apolipoprotein E immunoreactivity within neurofibrillary tangles: relationship to Tau and PHF in Alzheimer's disease. Exp. Neurol. 132: 162-171.
111. Gomez-Ramos, P., E. J. Mufson, and M. A. Moran. 2001. Apolipoprotein E immunoreactivity in neurons and neurofibrillary degeneration of aged non-demented and Alzheimer's disease. Microsc. Res. Tech. 55: 48-58.
112. Schmechel, D. E., A. M. Saunders, W. J. Strittmatter, B. J. Crain, C. M. Hulette, S. H. Joo, M. A. Pericak-Vance, D. Goldgaber, and A. D. Roses. 1993. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90: 9649-9653.
113. Veinbergs, I., A. Everson, Y. Sagara, and E. Masliah. 2002. Neurotoxic effects of apolipoprotein E4 are mediated via dysregulation of calcium homeostasis. J. Neurosci. Res. 67: 379-387.
114. Masliah, E., M. Mallory, M. Alford, R. DeTeresa, L. A. Hansen, D. W. McKeel, Jr., and J. C. Morris. 2001. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology. 56: 127-129.
115. Smith, J. D. 2000. Apolipoprotein E4: an allele associated with many diseases. Ann. Med. 32: 118-127.
116. Isbir, T., B. Agachan, H. Yilmaz, M. Aydin, I. Kara, E. Eker, and D. Eker. 2001. Apolipoprotein-E gene polymorphism and lipid profiles in Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen. 16: 77-81.
117. Hayashi, H., U. Igbavboa, H. Hamanaka, M. Kobayashi, S. C. Fujita, W. G. Wood, and K. Yanagisawa. 2002. Cholesterol is increased in the exofacial leaflet of synaptic plasma membranes of human apolipoprotein E4 knock-in mice. Neuroreport. 13: 383-386.
118. Kiener, P. A., P. M. Davis, J. L. Murray, S. Youssef, B. M. Rankin, and M. Kowala. 2001. Stimulation of inflammatory, responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int. Immunopharmacol. 1: 105-118.
119. Buxbaum, J. D., E. I. Cullen, and L. T. Friedhoff. 2002. Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. Front. Biosci. 7: a50-a59.
120. Jick, H., G. L. Zornberg, S. S. Jick, S. Seshadri, and D. A. Drachman. 2000. Stafins and the risk of dementia. Lancet. 356: 1627-1631.
121. Wolozin, B., W. Kellman, P. Ruosseau, G. G. Celesia, and G. Siegel. 2000. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57: 1439-1443.
122. Hajjar, I., J. Schumpert, V. Hirth, D. Wieland, and G. P. Eleazer. 2002. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J. Gerontol. A Biol. Sci. Med. Sci. 57: M414-M418.
123. Rockwood, K., S. Kirkland, D. B. Hogan, C. MacKnight, H. Merry, R. Verreault, C. Wolfson, and I. McDowell. 2002. Use of lipid-low ering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59: 223-227.
124. Scott, H. D., and K. Laake. 2001. Statins for the prevention of Alzheimer's disease. Cochrane Database Syst. Rev. 4: CD003160.
125. Tokuda, T., A. Tamaoka, S. Matsuno, S. Sakurai, H. Shimada, H. Morita, and S. Ikeda. 2001. Plasma levels of amyloid beta protein did not differ between subjects taking statins and not taking statins. Am. Neurol. 49: 546-547.
126. Saheki, A., T. Terasaki, I. Tamai, and A. Tsuji. 1994. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm. Res. 11: 305-311.
127. Tsuji, A., A. Saheki, I. Tamai, and T. Terasaki. 1993. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J. Pharmacol. Exp. Ther. 267: 1085-1090.
128. Wood, W. G., F. Schroeder, U. Igbavboa, N. A. Avdulov, and S. V. Chochina. 2002. Brain membrane cholesterol domains, aging and amyloid beta-peptides. Neurobiol. Aging. 23: 685-694.
129. Nakahara, K., M. Kuriyama, Y. Sonoda, H. Yoshidome, H. Nakagawa, J. Fujiyama, I. Higuchi, and M. Osame. 1998. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological and biochemical study. Toxicol. Appl. Pharmacol. 152: 99-106.
130. Sparks, D. L. 1997. Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer's disease? Ann. N. Y. Acad. Sci. 826: 128-146.
131. Corder, E. H., A. M. Saunders, W. J. Strittmatter, D. E. Schmechel, P. C. Gaskell, G. W. Small, A. D. Roses, J. L. Haines, and M. A. Pericak-Vance. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261: 921-923.
132. Narita, M., D. M. Holtzman, A. L. Schwartz, and G. Bu. 1997. Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J. Neurochem. 69: 1904-1911.
133. Kivipelto, M., E. L. Helkala, M. P. Laakso, T. Hanninen, M. Hallikainen, K. Alhainen, H. Soininen, J. Tuomilehto, and A. Nissinen. 2001. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 322: 1447-1451.
134. Borek, C. 2001. Antioxidant health effects of aged garlic extract. J. Nutr. 131 (Suppl.): 1010-1015.
135. Qureshi, A. A., N. Abuirmeileh, Z. Z. Din, C. E. Elson, and W. C. Burger. 1983. Inhibition of cholesterol and fatty acid biosynthesis in liver enzymes and chicken hepatocytes by polar fractions of garlic. Lipids. 18: 343-348.
136. Qureshi, A. A., T. D. Crenshaw, N. Abuirmeileh, N. Abuirmeileh, D. M. Peterson, and C. E. Elson. 1987. Influence of minor plant constituents on porcine hepatic lipid metabolism. Impact on serum lipids. Atherosclerosis. 64: 109-115.
137. Chi, M. S., E. T. Koh, and T. J. Stewart. 1982. Effects of garlic on lipid metabolism in rats fed cholesterol or lard. J. Nutr. 112: 241-248.
138. Chauhan, N. B. 2003. Anti-amyloidogenic effects of aged garlic extract in Tg2576. J. Herbal Pharmacotherapy. 3: 95-107.
139. Akama, K. T., C. Albanese, R. G. Pestell, and L.J. Van Eldik. 1998. Amyloid beta peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism. Proc. Natl. Acad. Sci. USA. 95: 5795-5800.
140. Geng, Z., Y. Rong, and B. H. Lau. 1987. S-allyl cysteine inhibits activation of nuclear factor kappa B in human T cells. Free Radic. Biol. Med. 23: 345-350.
141. Kim, K. M., S. B. Chun, M. S. Koo, W. J. Choi, T. W. Kim, Y. G. Kwon, H. T. Chung, T. R. Billiar, and Y. M. Kim. 2001. Differential regulation of NO availability from macrophages and endothelial cells by the garlic component S-allyl cysteine. Free Radic. Biol. Med. 30: 747-756.
142. Numagami, Y., and S. T. Ohnishi. 2001. S-allylcysteine inhibits free radical production, lipid peroxidation and neuronal damage in rat brain ischemia. J. Nutr. 131 (Suppl.): 1100-1105.
143. Jackson, R., B. McNeil, C. Taylor, G. Holl, D. Ruff, and E. T. Gwebu. 2002. Effect of aged garlic extract on caspase-3 activity in vitro. Nutr. Neurosci. 5: 287-290.
144. Peng, Q., A. R. Buz'Zard, and B. H. Lau. 2002. Neuroprotective effect of garlic compounds in amyloid-beta peptide-induced apoptosis in vitro. Med. Sci. Monit. 8: 328-337.
145. Nishiyama, N., T. Moriguchi, and H. Saito. 1997. Beneficial effects of aged garlic extract on learning and memory impairment in the senescence-accelerated mouse. Exp. Gerontol. 32: 149-160.
146. Nishiyama, N., T. Moriguchi, N. Morihara, and H. Saito. 2001. Ameliorative effect of S-allylcysteine, a major thioallyl constituent in aged garlic extract, on learning deficits in senescence-accelerated mice. J. Nutr. 131: 1093S-1095S.
147. Lang, T., D. Bruns, D. Wenzel, D. Riedel, P. Holroyd, C. Thiele, and R. Jahn. 2001. SNAREs are concentrated in cholesterol-dependent clusters that define docking and fusion sites for exocytosis. EMBO J. 20: 2202-2213.
148. Rodal, S. K., G. Skretting, O. Garred, F. Vilhardt, B. van Deurs, and K. Sandvig. 1999. Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol. Biol. Cell. 10: 961-974.
149. Subtil, A., I. Gaidarov, K. Kobylarz, M. A. Lampson, J. H. Keen, and T. E. McGraw. 1999. Acute cholesterol depletion inhibits clathrin-coated pit budding. Proc. Natl. Acad. Sci. USA. 96: 6775-6780.
150. Pike, L. J., X. Han, K. N. Chung, and R. W. Gross. 2002. Lipid rafts are enriched in arachidonic acid and plasmenylethanolamine and their composition is independent of caveolin-1 expression: a quantitative electrospray ionization/mass spectrometric analysis. Biochemistry. 41: 2075-2088.
151. Janmey, P. A., W. Xian, and L. A. Flanagan. 1999. Controlling cytoskeleton structure by phosphoinositide-protein interactions: phosphoinositide binding protein domains and effects of lipid packing. Chem. Phys. Lipids. 101: 93-107.
152. Raucher, D., T. Stauffer, W. Chen, K. Shen, S. Guo, J. D. York, M. P. Sheetz, and T. Meyer. 2000. Phosphatidylinositol 4,5-bis-phosphate functions as a second messenger that regulates cytoskeleton-plasma membrane adhesion. Cell. 100: 221-228.
153. Caroni, P. 2001. New EMBO members' review: actin cytoskeleton regulation through modulation of PI(4,5)P(2) rafts. EMBO J. 20: 4332-4336.
154. Botelho, R.J., M. Teruel, R. Dierckman, R. Anderson, A. Wells, J. D. York, T. Meyer, and S. Grinstein. 2000. Localized biphasic changes in phosphatidylinositol-4,5-bisphosphate at sites of phagocytosis. J. Cell Biol. 151: 1353-1368.